Yip, K., Conibear, J., Woolf, D., Tarver, K., Willis, B., Hall, S., Sun, F., Kuhan, H., Lambourne, B., Piskilidis, P., Kussaibati, R., Martin, L., Satar, N. A., Gray, C., Khan, A., Doherty, G., Prewett, S., Smith, M., Dancey, G., Patterson, D., Rimmer, Y., Hollingdale, A., Ingle, C., Tasigiannopoulos, Z., Aslam, S., Waite, K., Polychronis, A., Ghafoor, Q., Baijal, S., Newsom-Davis, T., Shah, R., Forster, M., Mulatero, C., Greystoke, A., Postmus, P., Blackhall, F., & Gilligan, D. (n.d.). 62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. Lung cancer, 103, S28–S29. http://access.bl.uk/ark:/81055/vdc_100041521865.0x000034